Aquestive Therapeutics (AQST) Price to FCF (2018 - 2026)

Aquestive Therapeutics has reported Price to FCF for 9 years, with the latest figure at 54.09 in Q2 2026.

• On a quarterly basis, Price to FCF fell 31.93% year-over-year to 54.09 in Q2 2026; TTM through Jun 2026 was 11.36, a 72.84% decrease from a year earlier, with the FY2025 full-year figure at 14.88, down 64.2% from the prior year.
• Price to FCF was 54.09 for Q2 2026 at Aquestive Therapeutics, down from 34.71 in the prior quarter.
• The five-year high for Price to FCF was 24.31 in Q3 2022, with the low at 92.17 in Q4 2025.
• Average Price to FCF over 5 years is 27.44, with a median of 31.87 recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Price to FCF soared 227.24% in 2022, then plunged 573.64% in 2023.
• Over 5 years, Price to FCF stood at 5.9 in 2022, then slumped by 573.64% to 27.92 in 2023, then plunged by 79.2% to 50.04 in 2024, then plunged by 84.2% to 92.17 in 2025, then jumped by 41.31% to 54.09 in 2026.
• The last three Price to FCF figures came in at 54.09 (Q2 2026), 34.71 (Q1 2026), and 92.17 (Q4 2025), per Business Quant data.